Syndax Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Clinical and Business Update

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. TSLA
6. META
7. RTX
8. SMCI
9. GOOGL
10. S

Go back to Syndax Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Clinical and Business Update

Syndax Pharmaceuticals (SNDX) Tops Q2 EPS by 27c

August 9, 2021 4:47 PM EDT

Syndax Pharmaceuticals (NASDAQ: SNDX) reported Q2 EPS of ($0.44), $0.27 better than the analyst estimate of ($0.71). Revenue for the quarter came in at $379 thousand versus the consensus estimate of $220 thousand.

As of June 30, 2021, Syndax had cash, cash equivalents and short-term investments of $253.1 million and 51.9 million shares and share equivalents issued and outstanding. This includes 3.3 million pre-funded warrants.

"The second quarter of 2021 was marked by significant progress advancing our pipeline of innovative therapeutics, and we... More